← Back to headlines
Amgen Exceeds Q2 Earnings Expectations, Raises Full-Year Outlook, Discontinues AMG 513
Amgen reported stronger-than-expected earnings for the second quarter of 2026 and subsequently raised its full-year financial outlook, while also announcing the discontinuation of its drug candidate AMG 513.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
